Purified capsular polysaccharides of streptococcus pneumoniae
Purified and sized capsular polysaccharides of Streptococcus pneumoniae serotypes 2, 15A, and 35B are prepared efficiently, addressing the need for improved pneumococcal conjugate vaccines by enhancing immunogenicity when conjugated to carrier proteins.
Patent Information
- Application Number
- JP2024130732
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-09-23
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for the development of additional multivalent pneumococcal conjugate vaccines containing purified and sized polysaccharides in a simple and efficient manner.
Purified and sized capsular polysaccharides of Streptococcus pneumoniae serotypes 2, 15A, 15C, and 35B are prepared with an average molecular weight of about 50 to 1000 kDa, achieved through purification and sizing methods including fermentation, lysing, centrifugation, filtration, and high-pressure homogenization.
The purified and sized polysaccharides are highly immunogenic when conjugated to carrier proteins, providing a basis for effective pneumococcal conjugate vaccines that induce a robust immune response.
Smart Images

Figure 2024160305000002 
Figure 2024160305000003 
Figure 2024160305000004
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to Indian Patent Application Nos. 201841031653 and 201841031654, filed on September 23, 2018, the specifications of which are incorporated herein by reference in their entireties. FIELD OF THEINVENTION The present invention relates to purified capsular polysaccharides of Streptococcus pneumoniae. More specifically, the present invention relates to purified and sized capsular polysaccharides of Streptococcus pneumoniae serotypes 2, 15A, 15C, and 35B, and methods for their preparation. [Background technology]
[0002] Streptococcus pneumoniae is a Gram-positive bacterium that is a major causative agent in invasive infections in animals and humans, such as septicemia, meningitis, otitis media, and lobar pneumonia. As part of the infection process, pneumococci readily attach to non-inflamed human epithelial cells of the upper and lower respiratory tract by lectin-like binding to eukaryotic carbohydrates.
[0003] Pneumococci are encapsulated with chemically linked polysaccharides that confer serotype specificity. There are over 90 known serotypes of pneumococci, and this capsule is the major virulence determinant of pneumococci, not only because it protects the inner surface of the bacteria from complement, but also because it is poorly immunogenic in itself. Anti-polysaccharide antibody levels are thought to predict protection against invasive pneumococcal disease. As a vaccine, the pneumococcal polysaccharide capsule can confer modest immunity to pneumococcus in individuals with developed or intact immune systems, but capsular polysaccharides conjugated to appropriate carrier proteins enable immune responses in infants and older adults who are also at highest risk for pneumococcal infection.
[0004] Pneumococcal vaccines include pneumococcal polysaccharide vaccines and pneumococcal conjugate vaccines. It is generally accepted that the protective efficacy of commercialized pneumococcal polysaccharide vaccines is more or less related to the concentration of antibodies induced upon vaccination. Current vaccines include multivalent pneumococcal polysaccharide vaccines (containing pneumococcal polysaccharides from two or more serotypes) and pneumococcal conjugate vaccines.
[0005] Pneumovax® 23 is a multivalent pneumococcal polysaccharide vaccine that contains unconjugated capsular polysaccharides from 23 pneumococcal serotypes, including serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F. The licensed Pneumovax® 23 has proven useful in preventing pneumococcal disease in adults, especially older and high-risk individuals. However, infants and young children respond poorly to this unconjugated pneumococcal polysaccharide vaccine.
[0006] Prevnar®-7 is a pneumococcal polysaccharide-protein conjugate vaccine that is designed to protect against the seven most frequently isolated polysaccharide serotypes (e.g., CRM 197 Since Prevnar®-7 began use in the United States in 2000, there has been a significant reduction in invasive pneumococcal disease (IPD) in children. 197 A 13-valent conjugate vaccine, Prevenar-13®, has been developed that contains 13 serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F conjugated to 1,4-diaminobenzidine, and is available in certain regions of the world with serotype coverage by Prevenar®-7. This was approved due to limitations in the scope of application.
[0007] Synflorix® is a pneumococcal conjugate vaccine containing ten polysaccharide serotypes 1, 4, 5, 6B, 7F, 9V, 14, 23F (PD) conjugated to protein D, serotype 18C conjugated to tetanus toxoid (TT), and serotype 19F conjugated to diphtheria toxoid (DT). Each of the serotype polysaccharides is coupled using 1-cyano-4-dimethylamino-pyridinium tetrafluoroborate (CDAP) under controlled pH.
[0008] US 9,492,559 B2 discloses an immunogenic composition comprising at least one glycoconjugate selected from the group consisting of a glycoconjugate from Streptococcus pneumoniae serotype 15B, a glycoconjugate from Streptococcus pneumoniae serotype 22F, a glycoconjugate from Streptococcus pneumoniae serotype 33F, a glycoconjugate from Streptococcus pneumoniae serotype 12F, a glycoconjugate from Streptococcus pneumoniae serotype 10A, a glycoconjugate from Streptococcus pneumoniae serotype 11A, and a glycoconjugate from Streptococcus pneumoniae serotype 8. WO 2019 / 050813 A1 discloses purified capsular polysaccharide from Streptococcus pneumoniae serotype 16F, and polysaccharide-protein conjugates thereof.
[0009] WO 2019 / 050814 A1 discloses purified capsular polysaccharides from Streptococcus pneumoniae serotypes 23A and 23B, as well as polysaccharide-protein conjugates thereof.
[0010] WO 2019 / 050815 A1 discloses purified capsular polysaccharide from Streptococcus pneumoniae serotype 24F, and polysaccharide-protein conjugates thereof.
[0011] WO 2019 / 050816 A1 discloses purified capsular polysaccharides from Streptococcus pneumoniae serotype 31, and polysaccharide-protein conjugates thereof. Summary of the Invention [Problem to be solved by the invention]
[0012] Despite these vaccines, there is a need for the development of additional multivalent pneumococcal conjugate vaccines that contain polysaccharides that are purified and sized in a simple and efficient manner. Accordingly, the inventors of the present invention have purified and sized the capsular polysaccharides of S. pneumoniae serotypes 2, 15A, 15C, and 35B in a simple and efficient manner. [Means for solving the problem]
[0013] The present invention relates to purified and sized capsular polysaccharides of Streptococcus pneumoniae serotype 2 having an average molecular weight of about 50-1000 kDa. The present invention also relates to purified and sized capsular polysaccharides of Streptococcus pneumoniae serotype 15A having an average molecular weight of about 50-1000 kDa.
[0014] The present invention also relates to purified and sized capsular polysaccharides of Streptococcus pneumoniae serotype 15C having an average molecular weight of about 50-1000 kDa. The present invention also relates to purified and sized capsular polysaccharides of Streptococcus pneumoniae serotype 35B having an average molecular weight of about 50-1000 kDa. [Brief description of the drawings]
[0015] [Figure 1] Figure 1A: 400 MHz one-dimensional (1D) 1H HMR spectrum of serotype 2 capsular polysaccharide in D2O at 50° C. Figure 1B: One-dimensional (1D) 1H HMR recognition region used for serotype 2 discrimination. [Diagram 2] Figure 2A: 400 MHz one-dimensional (1D) 1H HMR spectrum of serotype 15A capsular polysaccharide in D2O at 50° C. Figure 2B: One-dimensional (1D) 1H HMR signature region used for serotype 15A discrimination. [Diagram 3]Figure 3A: 400 MHz one-dimensional (1D) 1H HMR spectrum of the capsular polysaccharide of serotype 15C in D2O at 50° C. Figure 3B: One-dimensional (1D) 1H HMR signature region used for the discrimination of serotype 15C. [Figure 4] Figure 4A: 400 MHz one-dimensional (1D) 1H HMR spectrum of serotype 35B capsular polysaccharide in D2O at 50° C. Figure 4B: One-dimensional (1D) 1H HMR signature region used for serotype discrimination of 35B. [Diagram 5] Figure 5A: SEC-HPLC chromatogram showing the conjugation kinetics of serotype 2-CRM197. Figure 5B: SEC-HPLC chromatogram showing the conjugation kinetics of serotype 2-PsaA. [Figure 6] Figure 6A: (A) SEC-HPLC chromatogram showing the conjugation kinetics of serotype 15A-CRM197. Figure 6B: SEC-HPLC chromatogram showing the conjugation kinetics of serotype 15A-PsaA. [Figure 7] Figure 7A: (A) SEC-HPLC chromatogram showing the conjugation kinetics of serotype 15C-CRM197. Figure 7B: SEC-HPLC chromatogram showing the conjugation kinetics of serotype 15C-PsaA. [Figure 8] Figure 8A: (A) SEC-HPLC chromatogram showing the conjugation kinetics of serotype 35B-CRM197. Figure 8B: SEC-HPLC chromatogram showing the conjugation kinetics of serotype 35B-PsaA. [Figure 9] Serum antibody titers in rabbits immunized with PCV formulations. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] definition Throughout the present invention, the singular forms "a," "an," and "the" include plural referents unless the context clearly indicates otherwise. Similarly, unless the word "or" is expressly limited to mean only a single item in a list of two or more items to the exclusion of other items, the use of "or" in such a list should be interpreted to include (a) any single item in the list, (b) all items in the list, or (c) any combination of items in the list. In addition, the term "comprises," and the like, is used throughout the present invention to mean the inclusion of at least the recited features, such that any greater number of the same feature and / or one or more additional types of features are not excluded. Furthermore, various particular features, methods, or characteristics may be combined in any suitable manner in one or more embodiments.
[0017] The present invention is not intended to be exhaustive, nor is it intended to limit the present technology to the precise forms disclosed herein. Although specific embodiments are disclosed herein for illustrative purposes, those skilled in the relevant art will recognize that various equivalent modifications are possible without departing from the present technology. In some cases, known structures and functions have not been shown and / or described in detail to avoid unnecessarily obscuring the description of the embodiments of the present technology. Although steps of a method may be shown in a particular order herein, in alternative embodiments, the steps may have another suitable order. Similarly, certain embodiments of the present technology that are disclosed in the context of a particular embodiment may be combined in other embodiments or excluded in other embodiments. Furthermore, while advantages associated with certain embodiments may be disclosed in the context of this embodiment, other embodiments may also exhibit such advantages, and all embodiments need not exhibit such advantages or other advantages disclosed herein to be within the scope of the present technology. Thus, this disclosure and related technologies may be modified without departing from the spirit and scope of the present technology. The technique may include other embodiments not expressly shown and / or described herein.
[0018] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this method belongs. When a range of values is listed, it is understood that each intervening value between the upper and lower limits of the range, as well as any other stated or intervening value within the stated range, is encompassed in the methods and compositions. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed in the methods and compositions, subject to any specifically excluded limit in the stated range. When the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the methods, compositions, and combinations.
[0019] As used herein, the term "capsular polysaccharide" refers to the polysaccharide layer that is external to and continuous with the cell wall of Streptococcus pneumoniae serotypes 2, 15A, 15C, and 35B. As used herein, the term "carrier protein" refers to any protein to which a polysaccharide is attached, attached, or conjugated, typically for the purpose of enhancing or facilitating detection of the antigen by the immune system. Examples of carrier proteins include CRMPs, IgGs, and IgGs. 197 , PsaA, and tetanus toxoid (TT).
[0020] The terms "conjugate" or "conjugated" as used herein are used to mean that the S. pneumoniae capsular polysaccharide is covalently attached to a carrier protein.
[0021] The term "polysaccharide" as used herein refers to a complex carbohydrate made up of saccharide chains linked together by glycosidic bonds. The polysaccharide may contain at least 10, 20, 30, 40, or 50 or more saccharides.
[0022] The term "sized" or "sizing" as used herein refers to reducing the size of a native polysaccharide by various methods, which may include mechanical methods such as homogenization. Reducing the size of a native polysaccharide, or sizing, may provide various advantages, including: (1) providing greater homogeneity compared to native polysaccharides, (2) allowing control of the polysaccharide to protein ratio in the conjugate, and (3) the sized polysaccharide may provide greater stability to the composition. For purposes of the present invention, the native capsular polysaccharides of Streptococcus pneumoniae serotypes 2, 15A, 15C, and 35B are sized to an average molecular weight (Mw) of 50-1000 kDa.
[0023] The terms "molecular weight" or "molecular size" or "average molecular size" or "average molecular weight" of a polysaccharide, as used herein, refer to the weight average molecular weight (Mw) of the polysaccharide as measured by MALIS (Multi-Angle Laser Light Scattering). Detailed Description of the Invention The present invention relates to purified and sized capsular polysaccharides of Streptococcus pneumoniae serotypes 2, 15A, 15C, and 35B, and methods for their preparation.
[0024] The polysaccharides of the present invention are prepared by cultivating S. pneumoniae in optimized nutrients in a fermenter and lysing the cells at the end of fermentation by addition of sodium deoxycholate (DOC) or any conventional lysing agent. The recovered lysate broth is subjected to downstream purification to remove impurities such as proteins, nucleic acids, cell wall components, etc.
[0025] After fermentation, the DOC cell lysate is centrifuged in a batch or continuous centrifuge to separate the cell residues. The debris is removed. The pH of the cell-free broth is adjusted to acidic conditions and the temperature is raised before centrifugation. After centrifugation, the supernatant is passed through a depth filter, concentrated and diafiltered using an ultrafiltration (UF) membrane. Further impurities are removed from the polysaccharide preparation (retentate) by adding a surfactant followed by centrifugation. The surfactant-treated supernatant is then passed through a charcoal filter or through an activated carbon column, followed by exposing the filtered polysaccharide to SiO2 particles and then centrifuging. The supernatant is passed through a depth filter and the depth filtrate is passed through a carbon filter followed by a 0.22-0.6 μm filter. The filtrate is concentrated and diafiltered with a UF membrane and diafiltered against a 0.5-2% NaCl solution or water or buffer to obtain the polysaccharide in a substantially pure form.
[0026] The purified polysaccharides are sized either chemically at high pH or mechanically using a high pressure homogenizer. The sized polysaccharide preparation is concentrated to 5-25 mg / mL with a UF membrane. The retentate is passed through a 0.22 μm filter and frozen at <-20°C.
[0027] In one embodiment, the present invention provides purified and sized capsular polysaccharides of Streptococcus pneumoniae serotypes 2, 15A, 15C, and 35B having an average molecular weight (Mw) of 50-1000 kDa, preferably 100-1000 kDa, 200-800 kDa, 250-600 kDa, or 300-400 kDa, 70-150 kDa, or 75-125 kDa.
[0028] In some embodiments, the purified capsular polysaccharide of S. pneumoniae serotypes 2, 15A, 15C, and 35B prior to conjugation has an average molecular weight of 50 kDa to 1,000 kDa, in other such embodiments, the polysaccharide has an average molecular weight of 50 kDa to 750 kDa, 50 kDa to 500 kDa, 100 kDa to 1,000 kDa, 100 kDa to 750 kDa, or 100 kDa to 500 kDa.
[0029] The size of the capsular polysaccharides of the invention is reduced to the desired size after the purification procedure using various sizing techniques. The inventors have found that purified capsular polysaccharides from serotypes 2, 15A, 15C, and 35B conjugated to carrier proteins prepared according to the invention are highly immunogenic.
[0030] In one embodiment, the capsular polysaccharide of the invention comprises a pneumococcal polysaccharide from serotype 2 having an average molecular weight of about 80 kDa, 100 kDa, 200 kDa, 300 kDa, 400 kDa, 500 kDa, 700 kDa, or 1000 kDa.
[0031] In one embodiment, the capsular polysaccharide of the present invention comprises a pneumococcal polysaccharide from serotype 15A having an average molecular weight of about 80 kDa, 100 kDa, 200 kDa, 300 kDa, 400 kDa, 500 kDa, 700 kDa, or 1000 kDa.
[0032] In one embodiment, the capsular polysaccharide of the present invention comprises a pneumococcal polysaccharide from serotype 15C having an average molecular weight of about 80 kDa, 100 kDa, 200 kDa, 300 kDa, 400 kDa, 500 kDa, 700 kDa, or 1000 kDa.
[0033] In one embodiment, the capsular polysaccharide of the present invention comprises a pneumococcal polysaccharide from serotype 35B having an average molecular weight of about 80 kDa, 100 kDa, 200 kDa, 300 kDa, 400 kDa, 500 kDa, 700 kDa, or 1000 kDa.
[0034] In a further aspect, the present disclosure provides a sized Streptococcus pneumoniae serotype 15A capsular polysaccharide having a glycerol content in the range of 5-18%, preferably in the range of 5-10%.
[0035] In a further aspect, the present disclosure provides a sized Streptococcus pneumoniae serotype 15C capsular polysaccharide having a glycerol content in the range of 5-18%, preferably in the range of 5-10%.
[0036] In a further aspect, the present disclosure provides a composition having an acetate content in the range of 2-10%. The present invention provides a sized Streptococcus pneumoniae serotype 35B capsular polysaccharide, preferably in the range of 2-8%.
[0037] In a further aspect, the present disclosure provides a sized Streptococcus pneumoniae serotype 15A having an average molecular weight of 50-1000 kDa and a glycerol content in the range of 5-18%.
[0038] In a further aspect, the present disclosure provides a sized Streptococcus pneumoniae serotype 15C having an average molecular weight of 50-1000 kDa and a glycerol content in the range of 5-18%.
[0039] In a further aspect, the present disclosure provides an isolated Streptococcus pneumoniae serotype 35B having an average molecular weight of 50-1000 kDa and an acetate content in the range of 2-10%. The presence of glycerol phosphate side chains can be determined by measurement of glycerol using high performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD) after release of glycerol by treatment of the polysaccharide with hydrofluoric acid (HF).
[0040] In one embodiment, the present invention provides a pneumococcal conjugate vaccine, wherein a purified polysaccharide from Streptococcus pneumoniae serotype 2 having an average molecular weight of 50-1000 kDa is conjugated to a carrier protein selected from PsaA, CRM197, PspA, or tetanus toxoid (TT), the composition comprising a protein to polysaccharide (protein / PS) (w / w) percentage ratio of about 0.5 to about 2.0, preferably 0.7 to 1.2.
[0041] In one embodiment, the present invention provides a pneumococcal conjugate vaccine, comprising a purified polysaccharide from Streptococcus pneumoniae serotype 15A having an average molecular weight of 50-1000 kDa, PsaA, CRM 197, PspA, or tetanus toxoid (TT), the composition comprising a protein to polysaccharide (protein / PS) (w / w) percentage ratio of about 0.5 to about 2.0, preferably 0.7 to 1.2.
[0042] In one embodiment, the present invention provides a pneumococcal conjugate vaccine, wherein a purified polysaccharide from Streptococcus pneumoniae serotype 15C having an average molecular weight of 50-1000 kDa is conjugated to a carrier protein selected from PsaA, CRM197, PspA, or tetanus toxoid (TT), the composition comprising a protein to polysaccharide (protein / PS) (w / w) percentage ratio of about 0.5 to about 2.0 protein / PS, preferably 0.7 to 1.2.
[0043] In one embodiment, the present invention provides a pneumococcal conjugate vaccine, wherein a purified polysaccharide from Streptococcus pneumoniae serotype 35B having an average molecular weight of 50-1000 kDa is conjugated to a carrier protein selected from PsaA, CRM197, PspA, or tetanus toxoid (TT), the composition comprising a protein to polysaccharide (protein / PS) (w / w) percentage ratio of about 0.5 to about 2.0 protein / PS, preferably 0.7 to 1.2.
[0044] In one embodiment, the present invention provides an immunogenic composition comprising at least one glycoconjugate from Streptococcus pneumoniae serotype 2, at least one glycoconjugate from Streptococcus pneumoniae serotype 15A, at least one glycoconjugate from Streptococcus pneumoniae serotype 15C, and at least one glycoconjugate from 35B.
[0045] In one aspect the immunogenic composition of the invention further comprises a glycoconjugate from Streptococcus pneumoniae serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 14, 15B, 16F, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 31, 33F conjugated to a carrier protein selected from PsaA, CRM197, PspA, tetanus toxoid (TT), or a combination of CRM197 and PspA, or a combination of CRM197 and tetanus toxoid, or a combination of PsaA and tetanus toxoid, or a combination of CRM197, PspA and tetanus toxoid.
[0046] In another aspect, the immunogenic composition is a pneumococcal conjugate composition of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 25 or higher valency.
[0047] In another embodiment, the immunogenic composition is multivalent and comprises 8 pneumococcal polysaccharide conjugates (8-valent), 9 pneumococcal polysaccharide conjugates (9-valent), 10 pneumococcal polysaccharide conjugates (10-valent), 11 pneumococcal polysaccharide conjugates (11-valent), 12 pneumococcal polysaccharide conjugates (12-valent), 13 pneumococcal polysaccharide conjugates (13-valent), 14 pneumococcal polysaccharide conjugates (14-valent), 15 pneumococcal polysaccharide conjugates (15-valent), 16 pneumococcal polysaccharide conjugates (16-valent), 17 pneumococcal polysaccharide conjugates (17-valent), 18 pneumococcal polysaccharide conjugates (18-valent), 19 pneumococcal polysaccharide conjugates (19-valent), 20 pneumococcal polysaccharide conjugates (20-valent), 21 pneumococcal polysaccharide conjugates (21-valent), 22 pneumococcal polysaccharide conjugates (22-valent), 23 pneumococcal polysaccharide conjugates (23-valent), 24 pneumococcal polysaccharide conjugates (24-valent), 25 pneumococcal polysaccharide conjugates (25-valent), 26 pneumococcal polysaccharide conjugates (26-valent), 27 pneumococcal polysaccharide conjugates (27-valent), 28 pneumococcal polysaccharide conjugates (28-valent), 29 pneumococcal polysaccharide conjugates (29-valent), 30 pneumococcal polysaccharide conjugates (30-valent), 31 pneumococcal polysaccharide conjugates (31- These include pneumococcal polysaccharide conjugates (17-valent), 18 pneumococcal polysaccharide conjugates (18-valent), 19 pneumococcal polysaccharide conjugates (19-valent), 20 pneumococcal polysaccharide conjugates (20-valent), 21 pneumococcal polysaccharide conjugates (21-valent), 22 pneumococcal polysaccharide conjugates (22-valent), 23 pneumococcal polysaccharide conjugates (23-valent), 24 pneumococcal polysaccharide conjugates (24-valent), 25 pneumococcal polysaccharide conjugates (25-valent), and 26 pneumococcal polysaccharide conjugates (26-valent).
[0048] In yet another embodiment, the present invention provides an immunogenic composition comprising purified capsular polysaccharides of Streptococcus pneumoniae serotypes 2, 15A, 15C, and 35B having an average molecular weight of about 50-1000 kDa conjugated to a carrier protein.
[0049] In one aspect of the invention, the immunogenic composition comprises a Streptococcus pneumoniae polysaccharide, which polysaccharide serotype has been sized by a factor of up to 2, 3, 4, 5, 6, 7, 8, 9, or 10. The term "sized by a factor of up to 2" means that the saccharide has been subjected to a process intended to reduce the size of the saccharide but retain more than half the size of the native polysaccharide.
[0050] A polysaccharide that has not been subjected to the process of sizing techniques is referred to as a native polysaccharide. Although the polysaccharide may be slightly reduced in size during normal purification procedures or due to degradation during conjugation, the polysaccharide may still be referred to as a native polysaccharide.
[0051] The size of the capsular polysaccharide may be reduced by a variety of mechanical means known in the art (eg, high pressure techniques such as microfluidization, Emulsiflex™, high pressure homogenization, sonication, or Gaulin homogenization).
[0052] High pressure homogenization involves pumping the process stream through channels of sufficiently small dimensions. High shear rates are achieved by applying higher homogenization pressures and the exposure time can be increased by recirculating the feed stream through the homogenizer.
[0053] In another embodiment, the present invention provides a pneumococcal polysaccharide-protein conjugate vaccine composition comprising a capsular polysaccharide from Streptococcus pneumoniae serotype 2 conjugated to a carrier protein, wherein the polysaccharide-protein conjugate has an average molecular weight in the range of from 500 kDa to about 10,000 kDa and a percentage ratio of protein to polysaccharide (protein / PS) (w / w) of from about 0.5 to about 2.0, preferably from 0.7 to 1.2.
[0054] In another embodiment, the present invention provides a pneumococcal polysaccharide-protein conjugate vaccine composition comprising a capsular polysaccharide from Streptococcus pneumoniae serotype 15A conjugated to a carrier protein, wherein the polysaccharide-protein conjugate has an average molecular weight in the range of from 500 kDa to about 10,000 kDa and a percentage ratio of protein to polysaccharide (protein / PS) (w / w) of from about 0.5 to about 2.0, preferably from 0.7 to 1.2.
[0055] In another embodiment, the present invention provides a pneumococcal polysaccharide-protein conjugate vaccine composition comprising a capsular polysaccharide from Streptococcus pneumoniae serotype 15C conjugated to a carrier protein, wherein the polysaccharide-protein conjugate has an average molecular weight in the range of from 500 kDa to about 10,000 kDa and a percentage ratio of protein to polysaccharide (protein / PS) (w / w) of from about 0.5 to about 2.0, preferably from 0.7 to 1.2.
[0056] In another embodiment, the present invention provides a pneumococcal polysaccharide-protein conjugate vaccine composition comprising a capsular polysaccharide from Streptococcus pneumoniae serotype 35B conjugated to a carrier protein, wherein the polysaccharide-protein conjugate has an average molecular weight in the range of from 500 kDa to about 10,000 kDa and a percentage ratio of protein to polysaccharide (protein / PS) (w / w) of from about 0.5 to about 2.0, preferably from 0.7 to 1.2.
[0057] The polysaccharide protein conjugate of the present invention has an average molecular weight in the range of 500 kDa to about 5000 kDa, 1,000 kDa to about 10,000 kDa, about 1,500 kDa to about 15,000 kDa, about 2,000 kDa to about 20,000 kDa, about 2,500 kDa to about 25,000 kDa, or about 3,000 kDa to about 30,000 kDa.
[0058] In another embodiment, the present invention provides a pneumococcal conjugate vaccine composition comprising purified pneumococcal polysaccharide and a carrier protein having a percent protein to polysaccharide (Protein / PS) ratio of about 0.5 to about 2.0, preferably 0.7 to 1.2.
[0059] In a preferred embodiment, the present invention provides a pneumococcal conjugate vaccine composition comprising purified polysaccharide from Streptococcus pneumoniae serotypes 2, 15A, 15C, and 35B, having an average molecular weight of 50-1000 kDd, conjugated to a carrier protein selected from PsaA, CRM197, PspA, tetanus toxoid (TT), or a combination of CRM197 and PspA, or a combination of CRM197 and tetanus toxoid, or a combination of PsaA and tetanus toxoid, or a combination of CRM197, PspA, and tetanus toxoid, wherein the composition comprises a percentage ratio of protein to polysaccharide (protein / polysaccharide) of about 0.5 to about 2.0, preferably 0.7 to 1.2.
[0060] In another embodiment, the present invention provides a pneumococcal conjugate vaccine composition comprising one or more purified pneumococcal capsular polysaccharide serotypes each independently conjugated to a carrier protein, wherein each polysaccharide-protein conjugate has an average molecular weight of from about 1,500 kDa to about 15,000 kDa.
[0061] In other embodiments, the purified pneumococcal polysaccharides may be activated (e.g. chemically) prior to conjugation to one or more carrier proteins. Each activated pneumococcal polysaccharide may be independently conjugated to a carrier protein forming a polysaccharide-protein conjugate (e.g. glycoconjugate).
[0062] In some embodiments, the purified pneumococcal polysaccharides of the invention may be chemically activated and subsequently conjugated to a carrier protein according to known techniques (e.g., those described in U.S. Pat. Nos. 4,365,170, 4,673,574, and 4,902,506). For example, pneumococcal polysaccharides may be activated by random oxidative cleavage of one or more adjacent hydroxyl groups of the carbohydrate, oxidation of the terminal hydroxyl groups to aldehydes using an oxidizing agent such as a periodate (e.g., sodium periodate, potassium periodate, or periodic acid), and formation of one or more reactive aldehyde groups.
[0063] Similarly, purified pneumococcal polysaccharides of the invention may be activated with CDAP (1-cyano-4-dimethylamino-pyridinium tetrafluoroborate) and then conjugated to one or more carrier proteins (e.g., PsaA, CRM197, PspA, or combinations thereof). In other embodiments, pneumococcal polysaccharides activated with CDAP to form cyanate esters may be conjugated directly to one or more carrier proteins or may be conjugated via a spacer (e.g., a linker) that may be coupled to an amino group on the carrier protein. In some embodiments, the spacer may be cystamine or cysteamine, which generates a thiolated polysaccharide that can be attached to a carrier protein via a thioether linkage to a maleimide-activated protein (e.g., using GMBS) or via a thioether linkage to a haloacetylated carrier protein (e.g., using iodoacetimide, iodoacetimide ethyl, HCl, SIAB, SIA, SBAP, and / or N-succinimidyl bromoacetate). In other embodiments, hexanediamine or adipic dihydrazide (ADH) is used to attach a cyanate ester, and carbodiimide (e.g., EDAC or EDC) chemistry is used to conjugate an amino-derivatized sugar to a carrier protein via a carboxyl group on the carrier protein. Such conjugates are described in WO 93 / 15760, WO 95 / 08348, WO 96 / 29094, and Chu et al., 1983, Infect. Immunity 40:245-256.
[0064] Other activation and / or conjugation techniques suitable for use in the polysaccharide-protein conjugates and vaccine compositions of the invention include the use of carbodiimides, hydrazides, active esters, norborane, p-nitrobenzoic acid, N-hydroxysuccinimide, S-NHS, EDC, TSTU, and other methods described in WO 98 / 42721. For example, conjugation may involve a carbonyl linker that may be formed by reaction of a free hydroxyl group of the saccharide with CDI (Bethell et al., 1979, J. Biol. Chem. 254:2572-4; Hearn et al., 1981, J. Chromatogr. 218:509-18) and subsequent conjugation with the protein to form a carbamate bond. In some embodiments, the anomeric terminal The end can be reduced to a primary hydroxyl group, optionally protected / deprotected of the primary hydroxyl group, reacted with CDI to form a CDI carbamate intermediate, and coupled to an amino group on the protein.
[0065] For example, another activation and / or conjugation technique suitable for use in the polysaccharide-protein conjugates and vaccine compositions of the present invention includes the following method: sized pneumococcal polysaccharide (e.g., about 6 mL of sized polysaccharide at a concentration of about 10 mg / mL) and CDAP (e.g., about 100 mg / mL (w / v) in acetonitrile) can be mixed in a ratio of about 1:about 1 in a glass vial (e.g., by stirring for about 1 minute). The pH of the polysaccharide solution can be adjusted as necessary (e.g., adjusted to about 9.25 M with about 0.2 M triethylamine and stirred for 3 minutes at room temperature). In addition, PsaA (about 4 mL of a solution with a concentration of about 15 mg / mL) can be slowly added to the activated pneumococcal polysaccharide (e.g., in a ratio of about 1:about 1 (Ps:carrier protein)). The pH of the reaction can be adjusted (e.g., to about 9.05 using 0.2 M trimethylamine) and the reaction can be continued (e.g., by stirring at room temperature for 5 hours). The reaction mixture can be quenched (e.g., by the addition of an excess concentration of glycine).
[0066] In some embodiments, the reaction mixture may be diafiltered using a membrane (e.g., a 100K MWCO membrane) and purified by size exclusion chromatography. The diafiltered and purified fractions may be analyzed using SEC-MALLS and anthrone methods. The analytical fractions containing the conjugate may be pooled and sterile filtered (e.g., using a 0.2 μm filter).
[0067] After conjugation of the pneumococcal polysaccharide to one or more carrier proteins, the polysaccharide-protein conjugate may be purified (e.g., enriched in terms of the amount of polysaccharide-protein conjugate) by various techniques, including, but not limited to, concentration / diafiltration operations, precipitation / elution, column chromatography, and depth filtration. For example, after the conjugate is purified, it may be combined to formulate a pneumococcal polysaccharide-protein conjugate composition of the invention that may be used as a vaccine.
[0068] In one embodiment, the invention provides a 17-valent pneumococcal conjugate vaccine composition comprising a polysaccharide from serotypes of Streptococcus pneumoniae, including 2, 15A, 15C, and 35B, as well as additional serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, conjugated to a carrier protein.
[0069] In one embodiment, the invention provides a 17-valent pneumococcal conjugate vaccine composition comprising a polysaccharide from a serotype of Streptococcus pneumoniae, including serotypes 2, 15A, 15C, and 35B, and additional serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, conjugated to a carrier protein, wherein the carrier protein is selected from PsaA, CRM197, PspA, tetanus toxoid (TT).
[0070] In one embodiment, the invention relates to a 24-valent pneumococcal conjugate vaccine composition comprising polysaccharides from at least three pneumococcal serotypes selected from 2, 15A, 15C, and 35B, and additional serotypes including 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 14, 18C, 19A, 19F, 20A, 20B, 22F, 23F, 24F, 33F, wherein the 24 serotypes are conjugated to a carrier protein, and the A 24-valent pneumococcal conjugate vaccine composition is provided in which the carrier protein is selected from PsaA, CRM197, PspA, tetanus toxoid (TT), or a combination of CRM197 and PspA, or a combination of CRM197 and tetanus toxoid, or a combination of PsaA and tetanus toxoid, or a combination of CRM197, PsaA, and tetanus toxoid.
[0071] In one embodiment, the present invention relates to a 24-valent pneumococcal conjugate vaccine composition comprising polysaccharides from at least two pneumococcal serotypes selected from 2, 15A, 15C, and 35B, and additional serotypes including 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F, wherein the 24 serotypes are The present invention provides a 24-valent pneumococcal conjugate vaccine composition in which the pneumococcal pneumoniae conjugate is conjugated to a carrier protein selected from PsaA, CRM197, PspA, tetanus toxoid (TT), or a combination of CRM197 and PsaA, or a combination of CRM197 and tetanus toxoid, or a combination of PsaA and tetanus toxoid, or a combination of CRM197, PsaA, and tetanus toxoid.
[0072] In one embodiment, the invention relates to a multivalent pneumococcal conjugate vaccine composition comprising polysaccharides from at least two pneumococcal serotypes selected from 2, 15A, 15C, and 35B, and one or more additional serotypes selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 20A, 20B, 22F, 23A, 23B, 23F, 24F, 33F. and wherein the serotype is conjugated to a carrier protein selected from PsaA, CRM197, PspA, tetanus toxoid (TT), or a combination of CRM197 and PsaA, or a combination of CRM197 and tetanus toxoid, or a combination of PsaA and tetanus toxoid, or a combination of CRM197, PsaA, and tetanus toxoid, to provide a multivalent pneumococcal conjugate vaccine composition.
[0073] In some embodiments, the invention provides a method of preparing a polysaccharide-protein conjugate of a pneumococcal vaccine composition described herein, further comprising formulating the polysaccharide-protein conjugate into a pneumococcal vaccine composition comprising an adjuvant, an excipient, and a buffer.
[0074] In some embodiments, the invention provides methods of preparing a polysaccharide-protein conjugate of a pneumococcal vaccine composition described herein, wherein the adjuvant is aluminum phosphate.
[0075] In another embodiment, a vaccine or immunogenic composition of the invention is used to prevent infection caused by a strain of Streptococcus pneumoniae. In some embodiments, the invention provides a method of treating a subject in need of treatment, comprising administering to the subject in need of treatment a pneumococcal vaccine composition described herein.
[0076] In some embodiments, the subject has a disease mediated by Streptococcus pneumoniae, such as invasive pneumococcal disease (IPD). In one embodiment, the subject is a human, e.g., an infant (under about 1 year old), a toddler (about 12 months to about 24 months old), a child (about 2 years to about 5 years old), an older child (about 5 years to about 13 years old), an adolescent (about 13 years to about 18 years old), an adult (about 18 years to about 65 years old), or an older adult (over about 65 years old).
[0077] In some embodiments, the present invention provides a method of eliciting an immune response to a S. pneumoniae capsular polysaccharide conjugate comprising administering to a subject a pneumococcal conjugate as described herein. The method includes administering an immunologically effective amount of a vaccine composition.
[0078] In one embodiment, a method of eliciting an immune response to a Streptococcus pneumoniae capsular polysaccharide conjugate comprising administering to a subject systemically, subcutaneously, and / or mucosally a pneumococcal conjugate vaccine composition described herein.
[0079] In some embodiments, the amount of each conjugate in a dose of the vaccine composition of the invention is sufficient to elicit an immunoprotective response (e.g., an immunoprotective response that does not cause significant side effects). The amount of each conjugate may vary depending on the pneumococcal serotype, but each dose of the vaccine composition may contain about 0.1 μg to about 50 μg of each pneumococcal polysaccharide, about 0.1 μg to about 10 μg, or about 1 μg to about 5 μg of each pneumococcal polysaccharide conjugated to each carrier protein, which comprises about 1.5 μg to about 5 μg of carrier protein.
[0080] In another embodiment, the present invention provides a pneumococcal polysaccharide-protein conjugate vaccine composition comprising 0.1 μg to about 10 μg of capsular polysaccharide from Streptococcus pneumoniae serotype 2 conjugated to 1.5 μg to about 5 μg of a carrier protein, wherein the polysaccharide-protein conjugate has an average molecular weight in the range of 500 kDa to about 15,000 kDa and a percent ratio of protein to polysaccharide (protein / PS) (w / w) of about 0.5 to about 2.0, preferably 0.7 to 1.2.
[0081] In another embodiment, the present invention provides a pneumococcal polysaccharide-protein conjugate vaccine composition comprising 0.1 μg to about 10 μg of capsular polysaccharide from Streptococcus pneumoniae serotype 15A conjugated to 1.5 μg to about 5 μg of a carrier protein, wherein the polysaccharide-protein conjugate has an average molecular weight in the range of 500 kDa to about 15,000 kDa and a percent ratio of protein to polysaccharide (protein / PS) (w / w) of about 0.5 to about 2.0, preferably 0.7 to 1.2.
[0082] In another embodiment, the present invention provides a pneumococcal polysaccharide-protein conjugate vaccine composition comprising 0.1 μg to about 10 μg of capsular polysaccharide from Streptococcus pneumoniae serotype 15C conjugated to 1.5 μg to about 5 μg of a carrier protein, wherein the polysaccharide-protein conjugate has an average molecular weight in the range of 500 kDa to about 15,000 kDa and a percent ratio of protein to polysaccharide (protein / PS) (w / w) of about 0.5 to about 2.0, preferably 0.7 to 1.2.
[0083] In another embodiment, the present invention provides a pneumococcal polysaccharide-protein conjugate vaccine composition comprising 0.1 μg to about 10 μg of capsular polysaccharide from Streptococcus pneumoniae serotype 35B conjugated to 1.5 μg to about 5 μg of a carrier protein, wherein the polysaccharide-protein conjugate has an average molecular weight in the range of 500 kDa to about 15,000 kDa and a percent ratio of protein to polysaccharide (protein / PS) (w / w) of about 0.5 to about 2.0, preferably 0.7 to 1.2.
[0084] In another embodiment, the present invention provides a CRM 197 A pneumococcal polysaccharide-protein conjugate vaccine composition comprising 0.5 μg to about 5 μg of capsular polysaccharide from Streptococcus pneumoniae serotype 2 conjugated to 1.5 μg to about 5 μg of a carrier protein, the polysaccharide-protein conjugate having an average molecular weight in the range of 500 kDa to about 15000 kDa and a protein to polysaccharide (protein / PS) ratio of about 0.5 to about 2.0, preferably 0.7 to 1.2. The present invention provides a pneumococcal polysaccharide-protein conjugate vaccine composition having a (w / w) percentage ratio.
[0085] In another embodiment, the present invention provides a CRM 197The present invention provides a pneumococcal polysaccharide-protein conjugate vaccine composition comprising 0.5 μg to about 5 μg of capsular polysaccharide from Streptococcus pneumoniae serotype 15A conjugated to 1.5 μg to about 5 μg of a carrier protein, the polysaccharide-protein conjugate having an average molecular weight in the range of 500 kDa to about 15,000 kDa and a percent ratio of protein to polysaccharide (protein / PS) (w / w) of about 0.5 to about 2.0, preferably 0.7 to 1.2.
[0086] In another embodiment, the present invention provides a pneumococcal polysaccharide-protein conjugate vaccine composition comprising 0.5 μg to about 5 μg of capsular polysaccharide from Streptococcus pneumoniae serotype 15C conjugated to 1.5 μg to about 5 μg of CRM197 carrier protein, wherein the polysaccharide-protein conjugate has an average molecular weight in the range of 500 kDa to about 15000 kDa and a percent ratio of protein to polysaccharide (protein / PS) (w / w) of about 0.5 to about 2.0, preferably 0.7 to 1.2.
[0087] In another embodiment, the present invention provides a pneumococcal polysaccharide-protein conjugate vaccine composition comprising 0.5 μg to about 5 μg of capsular polysaccharide from Streptococcus pneumoniae serotype 2 conjugated to 1.5 μg to about 5 μg of PsaA carrier protein, wherein the polysaccharide-protein conjugate has an average molecular weight in the range of 500 kDa to about 15,000 kDa and a percent ratio of protein to polysaccharide (protein / PS) (w / w) of about 0.5 to about 2.0, preferably 0.7 to 1.2.
[0088] In another embodiment, the present invention provides a pneumococcal polysaccharide-protein conjugate vaccine composition comprising 0.5 μg to about 5 μg of capsular polysaccharide from Streptococcus pneumoniae serotype 15A conjugated to 1.5 μg to about 5 μg of PsaA carrier protein, wherein the polysaccharide-protein conjugate has an average molecular weight in the range of 500 kDa to about 15,000 kDa and a percent ratio of protein to polysaccharide (protein / PS) (w / w) of about 0.5 to about 2.0, preferably 0.7 to 1.2.
[0089] In another embodiment, the present invention provides a pneumococcal polysaccharide-protein conjugate vaccine composition comprising 0.5 μg to about 5 μg of capsular polysaccharide from Streptococcus pneumoniae serotype 15C conjugated to 1.5 μg to about 5 μg of PsaA carrier protein, wherein the polysaccharide-protein conjugate has an average molecular weight in the range of 500 kDa to about 15,000 kDa and a percent ratio of protein to polysaccharide (protein / PS) (w / w) of about 0.5 to about 2.0, preferably 0.7 to 1.2.
[0090] In another embodiment, the present invention provides a pneumococcal polysaccharide-protein conjugate vaccine composition comprising 0.5 μg to about 5 μg of capsular polysaccharide from Streptococcus pneumoniae serotype 35B conjugated to 1.5 μg to about 5 μg of PsaA carrier protein, wherein the polysaccharide-protein conjugate has an average molecular weight in the range of 500 kDa to about 15,000 kDa and a percent ratio of protein to polysaccharide (protein / PS) (w / w) of about 0.5 to about 2.0, preferably 0.7 to 1.2.
[0091] In a preferred embodiment, the present invention provides a multivalent conjugate vaccine composition comprising PsaA, CRM 197and at least two polysaccharides from Streptococcus pneumoniae serotypes 2, 15A, 15C, and 35B having an average molecular weight of 50-1000 kDa conjugated to a carrier protein selected from PsaA, CRM197, PspA, and tetanus toxoid (TT), the composition comprising a percentage ratio of protein to polysaccharide (protein / PS) of about 0.5 to about 2.0, preferably 0.7 to 1.2. and additional polysaccharide protein conjugates from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 14, 16F, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 31, 33F conjugated to a carrier protein selected from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 14, 16F, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 31, 33F, 25A, 25B, 25C, 25D, 25E, 25F ...
[0092] The pneumococcal polysaccharide-protein conjugate vaccine composition of the present invention may be manufactured using known methods. For example, the pneumococcal polysaccharide-protein conjugate vaccine composition may be formulated with a pharma-ceutically acceptable diluent or vehicle (e.g., water or saline). In addition, the pneumococcal polysaccharide-protein conjugate vaccine composition may further comprise one or more of the following: a buffering agent, a preservative or stabilizer, a polysorbate, an adjuvant, such as an aluminum compound (e.g., aluminum hydroxide, aluminum phosphate, or aluminum hydroxyphosphate), and / or an excipient for lyophilization. The inclusion of any one of the above compounds in the pneumococcal polysaccharide-protein conjugate vaccine composition of the present invention may be selected depending on the mode and route of administration to the required subject, and may also be based on standard pharmaceutical practice.
[0093] The pneumococcal polysaccharide-protein conjugate vaccine composition of the present invention, when administered to a subject, induces the formation of antibodies capable of binding to serotypes 2, 15A, 15C, and 35B of S. pneumoniae as measured by a standard ELISA assay. The ELISA was performed according to the WHO recommended protocol. Briefly, Maxisorp™ ELISA plates were coated with PnCPS of a given serotype (1 μg / 50 μL / well using PBS; sterile, endotoxin-free, with 0.02% sodium azide). The plates were placed in a box with moist paper towels for humidification and incubated at 37° C.±2° C. for 5 hours, and then the plates were stored at 5° C.±3° C. until use. EXAMPLES
[0094] The following examples are provided to illustrate the present invention and are for illustrative purposes only and should not be construed as limiting the scope of the present invention. Example 1: A. Preparation of pneumococcal capsular polysaccharide serotypes 2, 15A, 15C, and 35B Cell banks of S. pneumoniae strains (serotypes 2, 15A, 15C, and 35B) were obtained from the Centre for Disease Control and Prevention, USA. Pre-seeding preparation: 0.4 μl of culture (Streptococcus pneumonia serotype 2) isolate 60 ml of complete Mueller Hinton (MH) medium was inoculated. The inoculated flasks were incubated at 35±1° C., 5±0.5% CO2 for 2-8 hours. Samples were withdrawn and examined for optical density at 600 nm. When the desired OD of 0.8±0.2 was reached, samples were withdrawn and examined for pH and Gram stain. Seeding preparation: After checking the purity of the pre-seeded culture by microscopy (Gram staining), 40 ml of the pre-seeded culture was , a 1-liter flask containing 760 mL of MH medium was inoculated. The inoculum was incubated at 35 ± 1°C and 5 ± 0.5% % CO2 for 3-11 hours. Samples were withdrawn and examined for optical density (OD) at 600 nm. Once the desired OD of 4 ± 2 was reached, samples were withdrawn for Gram staining, pH. Purity was confirmed by plating on blood agar plates. Fermentation / Cultivation: The 750 ml inoculum was inoculated into 15 liters of MH medium and supplemented with 30–50% glucose at a rate of 3–5 ml per min until the OD at 600 nm reached 6 ± 2 at 35 ± 1°C under 100–140 revolutions per min (RPM) at a pH of 7.1 ± 0.3. Inactivation: A 13% stock solution of sodium deoxycholate (DOC) was added to the fermenter broth to inactivate the culture broth and incubated for 10±2 hours. The DOC-treated cultures were harvested and centrifuged at 14000 relative centrifugal volume (RCF) at 20° C. After centrifugation, the supernatant was collected and processed for purification steps.
[0095] B. Purification of pneumococcal capsular polysaccharide serotype 2 The S. pneumoniae serotype 2 DOC cell lysate was centrifuged in a batch centrifuge to remove cell debris. The pH of the cell-free broth was then adjusted to 5.0, incubated for 4 hours, and centrifuged at 14000g for 45 minutes. After centrifugation, the supernatant was passed through a depth filter. The filtrate was then concentrated 4.2-fold and diafiltered (4-15 diavolumes) using a 30-300 kDa UF membrane. Further impurities were removed from the polysaccharide preparation (retentate) by adding detergent (CTAB 1%), incubating at 6°C for 30-90 minutes, followed by centrifugation at 9000-14500g for 15-60 minutes. The CTAB-treated supernatant was then passed through an activated charcoal column (30-300 g / L polysaccharide preparation). The carbon filtered polysaccharide preparation was exposed to SiO2 (silicon dioxide) particles (3-10%, containing salt) and incubated at 2-40°C for 15-120 min, followed by centrifugation at 9000-14500 g for 15-60 min. The supernatant was passed through a 2-50 μm depth filter and the depth filtrate was passed through a carbon filter followed by a 0.22-0.6 μm filter. The filtrate (0.22-0.6 μm) was then concentrated and diafiltered through a 30-300 kDa UF membrane and diafiltered with 0.5-2% NaCl solution or without salt in water or buffer to obtain the capsular polysaccharide serotype 2 in substantially pure form. Purified pneumococcal capsular polysaccharides from serotypes 15A and 15C were prepared using a similar procedure as described above for serotype 2.
[0096] C. Purification of pneumococcal capsular polysaccharide serotype 35B S. pneumoniae serotype 35B DOC cell lysate was centrifuged in a batch centrifuge to remove cell debris. The pH of the cell-free broth was then adjusted to 5.0, incubated for 4 hours, and centrifuged at 14000g for 45 minutes. After centrifugation, the supernatant was passed through a depth filter. The filtrate was then concentrated 7.5 times and diafiltered (4-15 diavolumes) using a 30-300 kDa UF membrane. Further impurities were removed from the polysaccharide preparation (retentate) by adding detergent (CTAB 1%), incubating at 6°C for 30-90 minutes, followed by centrifugation at 9000-14500g for 15-60 minutes. The CTAB-treated supernatant was then passed through an activated charcoal column (30-300 g / L polysaccharide preparation). The carbon filtered polysaccharide preparation was exposed to SiO2 (silicon dioxide) particles (3-10%, containing salt) and incubated at 2-40°C for 15-120 min, followed by centrifugation at 9000-14500 g for 15-60 min. The supernatant was passed through a 2-50 μm depth filter and the depth filtrate was passed through a carbon filter followed by a 0.22-0.6 μm filter. The filtrate (0.22-0.6 μm) was then concentrated and purified to a concentration of 30-300 kDa. a UF membrane and diafiltered with 0.5-2% NaCl solution or without salt in water or buffer to obtain capsular polysaccharide serotype 35B in substantially pure form.
[0097] D. Sizing of purified pneumococcal capsular polysaccharide serotype 2 The purified pneumococcal capsular polysaccharide serotype 2 obtained above was mechanically sized using a high pressure homogenizer at 100 MPa (1000 bar) for 1-20 cycles. The sized polysaccharide preparation was concentrated again to 15 mg / mL with a 30 kDa ultrafiltration (UF) membrane. The retentate was passed through a 0.22 μm filter and frozen at <-20°C. Sizing of pneumococcal capsular polysaccharide from serotype 35B was carried out using a similar procedure as described above for serotype 2.
[0098] e. Sizing of purified pneumococcal capsular polysaccharide serotype 15A Purified pneumococcal capsular polysaccharide serotype 15A was mechanically sized using a high pressure homogenizer at 150 MPa (1500 bar) for 1-20 cycles. The sized polysaccharide pneumococcal serotype 15A preparation was concentrated again to 15 mg / mL with a 30 kDa ultrafiltration (UF) membrane. The retentate was passed through a 0.22 μm filter and frozen at <-20°C.
[0099] f. Sizing of purified pneumococcal capsular polysaccharide serotype 15C Purified pneumococcal capsular polysaccharide serotype 15C was mechanically sized using a high pressure homogenizer at 120 MPa (1200 bar) for 1-20 cycles. The sized polysaccharide pneumococcal serotype 15A preparation was concentrated again to 15 mg / mL with a 30 kDa ultrafiltration (UF) membrane. The retentate was passed through a 0.22 μm filter and frozen at <-20°C.
[0100] NMR structural analysis of pneumococcal capsular polysaccharide serotypes 2, 15A, and 15C The polysaccharide identities of serotypes 2, 15A, and 15C were confirmed by NMR analysis. This analysis was carried out based on the methodology published by Abeygunawardana et.al., Development and Validation of an NMR based Identity Assay for polysaccharides, Analytical Biochemistry, 279, 226-240 (2000). Based on the NMR data in Figures 1 to 3, the polysaccharide identities were confirmed from the anomeric region of the NMR spectrum, and the sugars contained in each polysaccharide serotype 2, 15A, and 15C were identified from the peaks.
[0101] NMR structural analysis of pneumococcal capsular polysaccharide serotype 35B The identity of the polysaccharide of serotype 35B was confirmed by NMR analysis. This analysis was carried out by Abeygunawardana et.al., Development and Validation of an NMR based Identity Assay for The analysis was carried out based on the methodology published by W. H., et al., Analytical Biochemistry, 279, 226-240 (2000). Based on the NMR data in Figure 4. 1 H NMR spectral peak assignments were made according to data published by LMBeynon., JC Richards., MB Perry., PJ Kniskern, Characterization of the capsular antigen of Streptococcus pneumoniae serotype 35B, Canadian Journal of Chemistry, 73(1):41-48 (1995).
[0102] From pneumococcus serotypes 2, 15A, 15C, and 35B prepared as described above The salient characteristics of the purified and sized polysaccharides are shown in Table 1 below.
[0103] [Table 1]
[0104] Example 2: Preparation of carrier protein a. CRM 197 Preparation of CRM 197 may be prepared recombinantly according to the methods described in U.S. Pat. No. 5,614,382. Alternatively, CRM 197 is prepared recombinantly according to methods known in the literature or according to the methods disclosed in WO 2016 / 079755, WO 2017 / 081700, and WO 2018 / 193475. 197 may be purified by ultrafiltration, ammonium sulfate precipitation, and ion exchange chromatography, methods known in the art. b. Preparation of PsaA The PsaA gene was PCR amplified from S. pneumoniae serotype 4 without the hydrophobic leader peptide sequence. The gene sequence was verified and cloned into Escherichia coli using an in-house constructed vector (pBE66) for high expression.
[0105] The glycerol stock culture encoding the PsaA gene was revived in 20 mL of LB medium containing 1 mL of glycerol stock in a 150 mL Erlenmeyer flask. The culture was grown to a final OD of 3.5 OD at 37° C. under 200 rpm for approximately 6 hours. 600nm The recovery culture was transferred to 1 L of seed culture in a 5 L Erlenmeyer flask. The culture was incubated at 37° C. under 200 rpm for approximately 10 hours to a final OD600 of 3. nm The seed culture was aseptically transferred to a 20 L fermenter containing the following culture components: HyPeptone 6 g / L, yeast extract 12 g / L, dipotassium orthophosphate 13.5 g / L, ammonium phosphate dibasic 4 g / L, citric acid 1.7 g / L, MgSO4.7H2O 1.2 g / L, glucose 4 g / L, thiamine HCL 10 mg / L, and trace elements at 1 mL / L (e.g., trace elements for a 100 mL composition: FeCl3 2.7 g, ZnCl2 0.2 g, CoCl2.6H2O 0.2 g, Na2MoO4.2H2O 0.2 g, CuSO4 5H2O 0.1 g, boric acid 0.05 g, CaCl2 2H2O 0.1 g, concentrated HCL 10 mL). The initial fermentation was performed at OD 600nm The fermentation was started at 0.2 OD. The pH was maintained at 7±0.2 throughout the fermentation using 20% orthophosphoric acid and 12.5% ammonium hydroxide. Once the glucose level fell below 0.5 g / L, it was fed at a steady rate of 3-4 g / L / hr. A fed batch was started and DO% was maintained >20% throughout the fermentation by oxygen enrichment. Cells were grown in fermenters and cell pellets were harvested by centrifugation. Cells were lysed using a cell disrupter (Panda). The lysate was centrifuged at 10000g and the clear supernatant was subjected to purification.
[0106] Purification of PsaA was performed similarly to the procedure described in Larentis et al., 2011 (Protein expression and Purification 78(2011)38). Purification was further optimized by using mixed-mode chromatography (Ceramic Hydroxyapatite Type-II) after DEAE to achieve higher purity of PsaA.
[0107] Anion exchange chromatography: 30 mL of DEAE Sepharose (GE) resin was loaded into an XK16 / 20 column. The resin was washed with 5 column volumes of sterile distilled water, followed by 10 column volumes of 20 mM Tris, 1 mM EDTA, pH 8.0 (equilibration buffer). 30 mL of the supernatant was diluted to 100 mL with equilibration buffer, loaded onto the column, and the flow-through was collected. The column was washed with 5 volumes of equilibration buffer. PsaA was eluted with a 12-volume linear gradient (0-100% B). (Buffer A containing 20 mM Tris, 1 mM EDTA pH 8.0; Buffer B containing 20 mM Tris, 1 mM EDTA, 250 mM NaCl pH 8.0). After this, the column was washed with 20 mM Tris, 1 mM EDTA, 1 M NaCl, pH 8.0.
[0108] Mixed-mode chromatography: 25 ml of Ceramic Hydroxyapatite Type II (CHT-II) was packed into a column. The resin was washed with a volume of sterile distilled water, followed by 10 volumes of 20 mM Tris pH 6.8. Elution fractions from the DEAE resin, which clearly showed a major visible band of good concentration of PsaA at about 37 KD on SDA PAGE, were pooled and loaded onto CHT-II resin. The flow-through was collected and the column was washed with 5 column volumes of equilibration buffer. Protein was eluted with a 5 column volume step gradient of (15% B, 20% B, 50% B, and 100% B). Buffer A contained 20 mM Tris pH 6.8 and buffer B contained 250 mM phosphate buffer pH 6.8.
[0109] All elution fractions showing a clear band at the expected size of PsaA were pooled, concentrated with a 10 kDa MWCO cassette, and diafiltered against 20 mM phosphate buffer pH 7.5. The purified protein was loaded on an SDS-PAGE gel to assess purity.
[0110] Example 3: Conjugation of pneumococcal capsular polysaccharide serotypes 2, 15A, 15C, and 35B A. Pneumococcal capsular polysaccharide serotype 2 and CRM 197 Conjugation with Mechanically size-reduced polysaccharide serotype 2, 1000 mg (200.0 mL of 5.0 mg / mL concentration) and CDAP (100 mg / mL (w / v) in acetonitrile) 5.0 mL were mixed in a glass bottle in a ratio of 1.0:0.5 (PS:CDAP) and stirred for 1 min. The pH of the polysaccharide solution was adjusted to 9.0 with 12.0 mL of 0.2 M triethylamine and stirred at room temperature (RT) for 1 min. To the activated polysaccharide, 1000 mg CRM (66.7 mL of 15.0 mg / mL concentration) was slowly added in a ratio of 1.0:1.0 (PnP:CRM).
[0111] The pH of the reaction was adjusted to 9.0 with 2.8 mL of 0.2 M triethylamine and the reaction was allowed to continue under stirring at room temperature for 3-5 h, followed by quenching the reaction by adding excess glycine (100 mM). The conjugation kinetics of the reaction (Figure 5A) were monitored at each time point of the reaction using SEC-HPLC. I did.
[0112] The reaction mixture was diafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Fractions were analyzed by SEC-MALLS, Anthrone method, and fractions containing the conjugate were pooled and sterile filtered through a 0.2 pm filter. The average molecular weight of the resulting conjugate was 8168 kDa. B. Conjugation of pneumococcal capsular polysaccharide serotype 2 with PsaA 1000 mg of mechanically size-reduced polysaccharide serotype 2 (200.0 mL of 5.0 mg / mL concentration) and 5.0 mL of CDAP (100 mg / mL (w / v) in acetonitrile) were mixed in a ratio of 1.0:0.5 (PS:CDAP) in a glass vial and stirred for 1 min. The pH of the polysaccharide solution was adjusted to 9.0 with 16.0 mL of 0.2 M triethylamine and stirred for 1 min at room temperature (RT). The activated polysaccharide was added with PsaA 800 mg (53.33 mL of 15.0 mg / mL concentration) was added slowly in a ratio of 1.0:0.8 (PnP:PsaA).
[0113] The pH of the reaction was adjusted to 9.0 with 3.5 mL of 0.2 M triethylamine and the reaction was allowed to continue under stirring at room temperature for 3-5 h, followed by quenching by adding excess glycine (100 mM). The conjugation kinetics of the reaction (Figure 5B) was monitored at each time point of the reaction using SEC-HPLC.
[0114] The reaction mixture was diafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Fractions were analyzed by SEC-MALLS, Anthrone method, and fractions containing the conjugate were pooled and sterile filtered through a 0.2 pm filter. The average molecular weight of the resulting conjugate was 6295 kDa. C. Pneumococcal capsular polysaccharide serotype 15A and CRM 197 Conjugation with Mechanically size-reduced polysaccharide serotype 15A 1000 mg (15.0 mg / mL concentration 66.7 mL of PS and 10.0 mL of CDAP (100 mg / mL (w / v) in acetonitrile) were mixed in a ratio of 1.0:1.0 (PS:CDAP) in a glass bottle and stirred for 1 min. The pH of the polysaccharide solution was adjusted to 9.0 with 18.0 mL of 0.2 M triethylamine and stirred for 1 min at room temperature (RT). The activated polysaccharide was added with CRM 1971000 mg (53.3 mL of 15.0 mg / mL concentration) was added slowly in a ratio of 1.0:0.8 (PnP:CRM).
[0115] The pH of the reaction was adjusted to 9.0 with 1.0 mL of 0.2 M triethylamine and the reaction was allowed to continue under stirring at room temperature for 3-5 h, followed by quenching by adding excess glycine (100 mM). The conjugation kinetics of the reaction (Figure 6A) was monitored at each time point of the reaction using SEC-HPLC.
[0116] The reaction mixture was diafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Fractions were analyzed by SEC-MALLS, Anthrone method, and fractions containing the conjugate were pooled and sterile filtered through a 0.2 pm filter. The average molecular weight of the resulting conjugate was 4272 kDa. d. Conjugation of pneumococcal capsular polysaccharide serotype 15A with PsaA Mechanically size-reduced polysaccharide serotype 15A 1000 mg (14.0 mg / mL concentration 71.4 mL of PS and 10.0 mL of CDAP (100 mg / mL (w / v) in acetonitrile) were mixed in a ratio of 1.0:1.0 (PS:CDAP) in a glass bottle and stirred for 1 min. The pH of the polysaccharide solution was adjusted to 9.0 with 20.5 mL of 0.2 M triethylamine and stirred for 1 min at room temperature (RT). 1000 mg of saA (66.6 mL of 15.0 mg / mL concentration) was slowly added in a ratio of 1.0:1.0 (PnP:PsaA).
[0117] The pH of the reaction was adjusted to 9.0 with 0.9 mL of 0.2 M triethylamine and the reaction was allowed to continue under stirring at room temperature for 3-5 h, followed by quenching by adding excess concentration of glycine (100 mM). The conjugation kinetics of the reaction (FIG. 6B) was monitored at each time point of the reaction using SEC-HPLC.
[0118] The reaction mixture was diafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Fractions were analyzed by SEC-MALLS, Anthrone method, and fractions containing the conjugate were pooled and sterile filtered through a 0.2 pm filter. The average molecular weight of the resulting conjugate was 9776 kDa. e. Pneumococcal capsular polysaccharide serotype 15C and CRM 197 Conjugation with Mechanically size-reduced polysaccharide serotype 15C 1000mg (10.0mg / mL concentration 100.0 mL of PS and 15.0 mL of CDAP (100 mg / mL (w / v) in acetonitrile) were mixed in a ratio of 1.0:1.5 (PS:CDAP) in a glass bottle and stirred for 1 min. The pH of the polysaccharide solution was adjusted to 9.0 with 24.0 mL of 0.2 M triethylamine and stirred for 1 min at room temperature (RT). The activated polysaccharide was added with CRM 197 1000 mg (66.6 mL of 15.0 mg / mL concentration) was added slowly in a ratio of 1.0:1.0 (PnP:CRM).
[0119] The pH of the reaction was adjusted to 9.0 with 2.8 mL of 0.2 M triethylamine and the reaction was allowed to continue under stirring at room temperature for 3-5 h, followed by quenching by adding excess glycine (100 mM). The conjugation kinetics of the reaction (Figure 7A) was monitored at each time point of the reaction using SEC-HPLC.
[0120] The reaction mixture was diafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Fractions were analyzed by SEC-MALLS, Anthrone method, and fractions containing the conjugate were pooled and sterile filtered through a 0.2 pm filter. The average molecular weight of the resulting conjugate was 10490 kDa. f. Conjugation of Pneumococcal Capsular Polysaccharide Serotype 15C with PsaA Mechanically size-reduced polysaccharide serotype 15C 1000mg (10.0mg / mL concentration 100.0 mL of PS (100 mg / mL (w / v) in acetonitrile) and 15.0 mL of CDAP (100 mg / mL (w / v) in acetonitrile) were mixed in a ratio of 1.0:1.5 (PS:CDAP) in a glass bottle and stirred for 1 min. The pH of the polysaccharide solution was adjusted to 9.0 with 24.0 mL of 0.2 M triethylamine and stirred for 1 min at room temperature (RT). 1000 mg of PsaA (66.6 mL of 15.0 mg / mL concentration) was slowly added to the activated polysaccharide in a ratio of 1.0:1.0 (PnP:PsaA).
[0121] The pH of the reaction was adjusted to 9.0 with 2.8 mL of 0.2 M triethylamine and the reaction was allowed to continue under stirring at room temperature for 3-5 h, followed by quenching by adding excess glycine (100 mM). The conjugation kinetics of the reaction (FIG. 7B) was monitored at each time point of the reaction using SEC-HPLC.
[0122] The reaction mixture was diafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Fractions were analyzed by SEC-MALLS, Anthrone method, and fractions containing the conjugate were pooled and filtered through a 0.2 pm filter. The resulting conjugate had an average molecular weight of 8719 kDa. G. Pneumococcal capsular polysaccharide serotype 35B and CRM 197 Conjugation with Mechanically size-reduced polysaccharide serotype 35B 1000 mg (10.0 mg / mL concentration 100.0 mL of PS and 5.0 mL of CDAP (100 mg / mL (w / v) in acetonitrile) were mixed in a ratio of 1.0:0.5 (PS:CDAP) in a glass bottle and stirred for 1 min. The pH of the polysaccharide solution was adjusted to 9.0 with 5.0 mL of 0.2 M triethylamine and stirred for 1 min at room temperature (RT). The activated polysaccharide was added with CRM 197 1000 mg (66.7 mL of 15.0 mg / mL concentration) was added slowly in a ratio of 1.0:1.0 (PnP:CRM).
[0123] The pH of the reaction was adjusted to 9.0 with 1.6 mL of 0.2 M triethylamine and the reaction was allowed to continue under stirring at room temperature for 3-5 h, followed by quenching by adding excess concentration of glycine (100 mM). The conjugation kinetics of the reaction (FIG. 8A) was monitored at each time point of the reaction using SEC-HPLC.
[0124] The reaction mixture was diafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Fractions were analyzed by SEC-MALLS, Anthrone method, and fractions containing the conjugate were pooled and sterile filtered through a 0.2 pm filter. The average molecular weight of the resulting conjugate was 8572 kDa. h. Conjugation of pneumococcal capsular polysaccharide serotype 35B with PsaA 1000 mg of mechanically size-reduced polysaccharide serotype 35B (142.8 mL of 7.0 mg / mL concentration) and 6.0 mL of CDAP (100 mg / mL (w / v) in acetonitrile) were mixed in a glass bottle in a ratio of 1.0:0.6 (PS:CDAP) and stirred for 1 min. The pH of the polysaccharide solution was adjusted to 9.0 with 7.0 mL of 0.2 M triethylamine and stirred for 1 min at room temperature (RT). 1000 mg of PsaA (66.6 mL of 15.0 mg / mL concentration) was slowly added to the activated polysaccharide in a ratio of 1.0:1.0 (PnP:PsaA).
[0125] The pH of the reaction was adjusted to 9.0 with 2.2 mL of 0.2 M triethylamine and the reaction was allowed to continue under stirring at room temperature for 3-5 h, followed by quenching by adding excess concentration of glycine (100 mM). The conjugation kinetics of the reaction (FIG. 8B) was monitored at each time point of the reaction using SEC-HPLC.
[0126] The reaction mixture was diafiltered and concentrated using a 100 kDa MWCO TFF membrane. The concentrate was purified by size exclusion chromatography. Fractions were analyzed by SEC-MALLS, Anthrone method, and fractions containing the conjugate were pooled and sterile filtered through a 0.2 pm filter. The average molecular weight of the resulting conjugate was 6944 kDa.
[0127] Example 4: Formulation of a pneumococcal capsular polysaccharide-protein conjugate vaccine The multivalent conjugate vaccine was prepared using the CRN 197 The conjugates were formulated as 0.5 mL doses containing 2.2 μg of each pneumococcal polysaccharide from serotypes 2, 15A, 15C, and 35B conjugated to approximately 8-10 μg of protein. All conjugates were formulated as 0.5 mL doses containing 2.2 μg of each pneumococcal polysaccharide from serotypes 2, 15A, 15C, and 35B conjugated to approximately 8-10 μg of protein. 3+ The equivalent of 0.5 mg of 10 ... The vials were sealed with 3 mm sterile pink flip-off aluminum seals, followed by optical inspection and labeling of the filled vials. From this lot, several vials were randomly picked and analyzed for appearance, pH, osmolality, total polysaccharide and protein content (μg / SHD), % adsorption, and aluminum content (mg / SHD).
[0128] Example 5: Formulation of a pneumococcal capsular polysaccharide-protein conjugate vaccine Multivalent conjugate vaccines were formulated as 0.5 mL doses containing 2.2 μg of each pneumococcal polysaccharide from serotypes 2, 15A, 15C, and 35B conjugated to approximately 8-10 μg of PsaA carrier protein, as prepared in Example 3. All conjugates were adsorbed onto aluminum. All conjugates were adsorbed onto aluminum per 0.5 mL dose. 3+ 0.5 mg of 10 ...
[0129] Example 5: Formulation of a pneumococcal capsular polysaccharide-protein conjugate vaccine The 24-valent conjugate vaccine was administered to 197 The conjugates were formulated as 0.5 mL doses containing 2.2 μg each of pneumococcal polysaccharides from serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F (except 4.4 μg of 6B) conjugated to 25-40 μg of PsaA, and 2.2 μg each of pneumococcal polysaccharides from serotypes 3, 6A, 8, 10A, 11A, 12F, 15A, 23A, 23B, 24F, and 35B conjugated to 25-40 μg of PsaA. All conjugates were formulated as 0.5 mL doses containing 2.2 μg each of pneumococcal polysaccharides from serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F conjugated to 25-40 μg of PsaA. 3+0.5 mg of glycerol was adsorbed onto aluminum phosphate gel. 0.9% W / V saline was used as the diluent and vehicle for this formulation, and the final formulation pH was adjusted to pH 6 using 1N hydrochloric acid. For effective adsorption after pH adjustment, this formulation was mixed for 2 hours under constant stirring. After 2 hours of blending, the formulated blend was aseptically filled into 3 mL sterile non-siliconized vials with a fill volume of 0.58 mL per vial, closed with sterile 13 mm rubber stoppers, and sealed with 13 mm sterile pink flip-off aluminum seals, followed by optical inspection and labeling of the filled vials. From this lot, several vials were randomly picked and sent for analysis for appearance, pH, osmolality, total polysaccharide and protein content (μg / SHD), % adsorbed, and aluminum content (mg / SHD).
[0130] Example 6: Immunization of rabbits with a 0.5 mL dose A) Immunization and ELISA Healthy rabbits, each weighing 1.5-2 kg, were kept in a contained facility. Rabbits were immunized with a single 0.5 mL dose of polyvalent PCV as described in Examples 4 and 5. Each group of 7 rabbits was immunized with the formulation on days 1, 15, and 29. Blood samples were collected on days 0 (pre-immunization), 15 (test bleed), and 36 (final bleed). Rabbit sera collected on days 0 (PD1) and 40 (PD3) were analyzed for serotype-specific immune responses using ELISA. The ELISA was performed according to the WHO recommended protocol. The ELISA was performed according to the WHO recommended protocol. Briefly, Maxisorp™ ELISA plates were coated with PnCPS of a given serotype. The ELISA was performed according to the WHO recommended protocol. ELISA plates were performed according to the O recommended protocol. Briefly, Maxisorp™ ELISA plates were coated with PnCPS of a given serotype (1 μg / 50 μL / well using PBS; sterile endotoxin-free, with 0.02% sodium azide). Plates were placed in a box with moist paper towels for humidification and incubated at 37° C.±2° C. for 5 hours, then the plates were stored at 5° C.±3° C. until use.
[0131] Test sera were pre-adsorbed with CWPS Mlti™ to eliminate background reactivity from cell wall polysaccharides. To achieve this, 2 μL of test sera and positive control sera were diluted with 998 μL of pre-adsorption solution (1 μL of CWPS Multi™ in 999 μL of 10% SuperBlock™ in 1 mL-PBST) to a final dilution of 1:500. The diluted samples were incubated at room temperature (25° C.±5° C.) for 1 hour with continuous shaking. Unbound PnCPS was removed by flicking the plate and free sites in the wells were blocked by adding 200 μL of blocker (20% SuperBlock™ in PBS). The plate was incubated at room temperature (25±5° C.) for 1 hour without shaking.
[0132] B) Addition of Test Samples and Controls To all wells except A1-A12, 50 μL of diluent (10% SuperBlock™ in PBST) was added. After this, 100 μL / well of pre-adsorbed test serum samples were added to A1-A10 and control serum samples were added to A11 and A12. Two-fold serial dilutions of the test samples were performed by transferring 50 μL from the first round to the second round etc. (i.e., from A1-A10 to H1-H10). Similarly, serial dilutions of the control sample (007SP) were performed from A11 and 12 to E11 and E12. Undiluted F11 and F12 to H11 and H12 were set as blanks. The plate was incubated at room temperature (25° C.±5° C.) for 2 hours without shaking. After this incubation step, the contents were discarded and the plate was washed three times with PBST (approximately 250 μL / well) either manually or by a plate washer.
[0133] C) Addition of primary antibody 50 μL / well of recombinant Protein A / G Peroxidase (diluted 1:20000 using 10% SuperBlock™ in PBST) was added to all wells and the plate was incubated for 1 hour at room temperature (25° C.±5° C.) without shaking. After this, the plate was washed 3 times with PBST (250 μL / well) either manually or with a plate washer.
[0134] D) Expression and reading The color reaction was developed by adding 50 μL / well of TMB substrate and incubated for 15 min at room temperature (25° C.±5° C.) without shaking. The reaction was stopped by adding 50 μL / well of 1.25 M sulfuric acid. The OD at 450 nm was measured.
[0135] E) Titer Estimation Antibody titers in immunized animals were assigned as the reciprocal of the dilution factor. An OD of twice the pre-immunization titer (approximately 0.2) was 450nm The highest dilution showing an antibody titer was reported as the titer. Serum antibody titers against each serotype were plotted and compared with the various treatment groups.
[0136] F) Immune response in rabbits Rabbits were immunized with the formulations described in Example 5. The study design consisted of Each consisted of two groups of 7 rabbits. The animals were immunized with 3 doses of the formulated vaccine.
[0137] Sera from the immunized rabbits were collected at the specified intervals. Serotype-specific IgG titer levels were estimated by ELISA, which was adapted from the WHO-recommended ELISA for evaluating serum antibody titers in human serum. Antibody titers were determined as ODs above the cut-off limit. 450nm Values were estimated as the maximum dilution of serum obtained. The IgG titer values of the animals before vaccination were used to calculate the geometric mean fold rise (GMFR) of serum IgG titers. After administration of the 24-valent PCV formulation described above, animals were found to have antibodies against each serotype of the conjugated polysaccharide in the vaccine, and therefore the vaccine is immunogenic.
[0138] As shown (Figure 9), titers were calculated based on the cutoff value (OD observed in preimmune serum). 450nm ELISA OD greater than 2x (approximately 0.1 OD value) 450nm is estimated as the highest serum dilution that resulted in a 100% immunization. The geometric mean fold rise (GMFR) for each serotype was plotted. Sera obtained after three doses of immunization (after dose 3) were used to assess immunogenicity. Black bars indicate pneumococcal polysaccharide conjugated to CRM197 and white inside bars indicate pneumococcal polysaccharide conjugated to PsaA.
[0139] From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the scope of the invention.
Claims
1. Purified and sized capsular polysaccharide of Streptococcus pneumoniae serotypes 2, 15A, 15C, or 35B having an average molecular weight (Mw) of 50-1000 kDa.
2. 2. The purified capsular polysaccharide of Streptococcus pneumoniae serotype 2, 15A, 15C, or 35B according to claim 1, having an average molecular weight (Mw) of 50 kDa to 750 kDa, 50 kDa to 500 kDa, 100 kDa to 1,000 kDa, 100 kDa to 750 kDa, or 100 kDa to 500 kDa.
3. 2. The purified capsular polysaccharide of Streptococcus pneumoniae serotype 15A or 15C according to claim 1, having a glycerol content in the range of 5-18%.
4. The purified capsular polysaccharide of Streptococcus pneumoniae serotype 15A according to claim 3, having a glycerol content of 5-10%.
5. The purified capsular polysaccharide of Streptococcus pneumoniae serotype 15C according to claim 3, having a glycerol content of 5-10%.
6. The purified capsular polysaccharide of Streptococcus pneumoniae serotype 35B according to claim 1, having an acetate content in the range of 2-10%, preferably in the range of 2-8%.
7. A method for preparing purified and sized capsular polysaccharides of Streptococcus pneumoniae serotypes, comprising the steps of: a. culturing Streptococcus pneumoniae serotype 2, 15A, 15C, or 35B in an appropriate culture medium; b. inactivating the culture broth of Streptococcus pneumoniae; c. centrifuging the culture broth of Streptococcus pneumoniae; d. purifying the capsular polysaccharides of said Streptococcus pneumoniae from the culture broth; and e. subjecting the purified pneumococcal capsular polysaccharides to high pressure homogenization to obtain sized capsular polysaccharides having an average molecular weight (MW) of 50-1000 kDa. The method includes:
8. 8. The method of claim 7, wherein the homogenization is carried out at a pressure in the range of 50 to 200 MPa (500 to 2000 bar).
9. A purified capsular polysaccharide of Streptococcus pneumoniae serotype 2, 15A, 15C, or 35B having an average molecular weight (Mw) of 50 to 1000 kDa, obtained by the method according to claim 7.
10. 1. A pneumococcal conjugate vaccine comprising at least one purified and sized capsular polysaccharide from Streptococcus pneumoniae serotypes 2, 15A, 15C, or 35B having an average molecular weight of 50-1000 kDa conjugated to a carrier protein, the composition comprising a protein to polysaccharide (protein / PS) (w / w) percentage ratio of about 0.5 to about 2.
0.
11. 11. The conjugate vaccine of claim 10, wherein the carrier protein is selected from PsaA, CRM197, PspA, tetanus toxoid (TT), or a combination thereof.
12. The composition comprises a polysaccharide from serotype 2 having an average molecular weight of 50-1000 kDa conjugated to PsaA, CRM197, PspA, or tetanus toxoid (TT), The pneumococcal conjugate vaccine of claim 10, wherein the product comprises a protein to polysaccharide (protein / PS) (w / w) percentage ratio of about 0.5 to about 2.0, preferably 0.7 to 1.
2.
13. 11. The pneumococcal conjugate vaccine of claim 10, comprising a polysaccharide from serotype 15A with an average molecular weight of 50-1000 kDa conjugated to a carrier protein selected from PsaA, CRM197, PspA or tetanus toxoid (TT), the composition comprising a protein to polysaccharide (protein / PS) (w / w) percentage ratio of about 0.5 to about 2.0, preferably 0.7 to 1.
2.
14. 11. The pneumococcal conjugate vaccine of claim 10, comprising a polysaccharide from serotype 15C, having an average molecular weight of 50-1000 kDa, conjugated to a carrier protein selected from PsaA, CRM197, PspA or tetanus toxoid (TT), the composition comprising a protein to polysaccharide (protein / PS) (w / w) percentage ratio of about 0.5 to about 2.0, preferably 0.7 to 1.
2.
15. 11. The pneumococcal conjugate vaccine of claim 10, comprising a polysaccharide from serotype 35B with an average molecular weight of 50-1000 kDa conjugated to a carrier protein selected from PsaA, CRM197, PspA or tetanus toxoid (TT), the composition comprising a protein to polysaccharide (protein / PS) (w / w) percentage ratio of about 0.5 to about 2.0, preferably 0.7 to 1.
2.
16. 16. The pneumococcal conjugate vaccine of any one of claims 10 to 15, wherein the conjugate has an average molecular weight in the following ranges: 500 kDa to 5000 kDa, 1,000 kDa to 10,000 kDa, 1,500 kDa to 15,000 kDa, 2,000 kDa to 20,000 kDa, 2,500 kDa to 25,000 kDa, or 3,000 kDa to 30,000 kDa.
17. 10. An immunogenic composition comprising at least one glycoconjugate from Streptococcus pneumoniae serotype 2, 15A, 15C, or 35B, wherein the polysaccharide in the glycoconjugate is a purified capsular polysaccharide according to claim 1.
18. 18. The immunogenic composition of claim 17, further comprising a glycoconjugate from Streptococcus pneumoniae serotype 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 14, 15B, 16F, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 31, 33F conjugated to a carrier protein selected from PsaA, CRM197, PspA, tetanus toxoid (TT), or a combination of carrier proteins.
19. 20. The composition of claim 17 or 18, wherein the composition is a multivalent immunogenic composition, being a pneumococcal conjugate composition of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 25 or higher valency.
20. 20. The immunogenic composition of claim 19, wherein the composition is a 24-valent pneumococcal conjugate composition comprising polysaccharides from at least three pneumococcal serotypes selected from 2, 15A, 15C, and 35B, and additional serotypes including 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 14, 18C, 19A, 19F, 20A, 20B, 22F, 23F, 24F, 33F, wherein the serotypes are conjugated to a carrier protein, and the carrier protein is selected from PsaA, CRM197, PspA, tetanus toxoid (TT).
21. 20. The immunogenic composition of claim 19, wherein the composition is a 24-valent pneumococcal conjugate comprising polysaccharides from at least two pneumococcal serotypes selected from 2, 15A, 15C, and 35B, and additional serotypes including 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 22F, 23A, 23B, 23F, 24F, 33F, wherein the serotypes are conjugated to a carrier protein selected from PsaA, CRM197, PspA, tetanus toxoid (TT).
22. 20. The immunogenic composition of claim 19, wherein the composition is a multivalent pneumococcal conjugate vaccine composition comprising polysaccharides from at least two pneumococcal serotypes selected from 2, 15A, 15C, and 35B, and one or more additional serotypes selected from 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 18C, 19A, 19F, 20A, 20B, 22F, 23A, 23B, 23F, 24F, 33F, wherein the serotypes are conjugated to a carrier protein selected from PsaA, CRM197, PspA, tetanus toxoid (TT).
23. 20. The immunogenic composition of claim 19, wherein the composition is a 17-valent pneumococcal conjugate vaccine composition comprising a polysaccharide from a serotype of Streptococcus pneumoniae conjugated to a carrier protein, the serotypes including 2, 15A, 15C, and 35B, and additional serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, and the carrier protein is selected from PsaA, CRM197, PspA, tetanus toxoid (TT).
24. 2. The purified capsular polysaccharide of claim 1, wherein the polysaccharide is useful for the preparation of a vaccine or immunogenic composition.
25. A vaccine according to any one of claims 10 to 16 or an immunogenic composition according to any one of claims 17 to 23, wherein the vaccine or immunogenic composition is useful for the prevention of Streptococcus pneumoniae infection.
Citation Information
Patent Citations
Sugar conjugation method
JP2016509081A
Streptococcus pneumoniae capsular polysaccharides and their conjugates
JP2017504661A
vaccine
WO2017067962A1
Saccharide-polypeptide conjugate compositions and methods of use thereof
WO2017173415A2
Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
WO2018064444A1
